Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith C Ferdinand

Showing results (41-50 of 287) with videos related to

Pageof 29
Sort By:
Journal of the American College of Cardiology|November 24, 2022
HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity?Keith C Ferdinand
Journal of the Cardiometabolic Syndrome|December 7, 2007
The cardiometabolic syndrome and cardiovascular disease in racial and ethnic minorities: new areas of research and interventionKeith C Ferdinand
Journal of the Cardiometabolic Syndrome|August 8, 2007
Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndromeKeith C Ferdinand
JACC. Advances|June 28, 2024
Overcoming Racial/Ethnic Disparities in Alzheimer Disease and Related Dementias: Time for a Closer LookKeith C Ferdinand
Annals of Translational Medicine|September 14, 2018
Global perspectives on cardiometabolic risk and cardiovascular disease: from basic science to bedsideKeith C Ferdinand
Journal of the National Medical Association|May 5, 2005
Managing cardiovascular risk in minority patientsKeith C Ferdinand
The American Journal of Cardiology|January 31, 2006
Coronary artery disease in minority racial and ethnic groups in the United StatesKeith C Ferdinand
Current Medical Research and Opinion|July 12, 2005
Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular diseaseKeith C Ferdinand
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 9, 2008
Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?Keith C Ferdinand
Expert Opinion on Pharmacotherapy|September 8, 2005
Rosuvastatin: a risk-benefit assessment for intensive lipid loweringKeith C Ferdinand
Pageof 29

Showing results (41-50 of 287) with videos related to

Sort By:
Pageof 29
Journal of the American College of Cardiology|November 24, 2022
HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity?Keith C Ferdinand
Journal of the Cardiometabolic Syndrome|December 7, 2007
The cardiometabolic syndrome and cardiovascular disease in racial and ethnic minorities: new areas of research and interventionKeith C Ferdinand
Journal of the Cardiometabolic Syndrome|August 8, 2007
Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndromeKeith C Ferdinand
JACC. Advances|June 28, 2024
Overcoming Racial/Ethnic Disparities in Alzheimer Disease and Related Dementias: Time for a Closer LookKeith C Ferdinand
Annals of Translational Medicine|September 14, 2018
Global perspectives on cardiometabolic risk and cardiovascular disease: from basic science to bedsideKeith C Ferdinand
Journal of the National Medical Association|May 5, 2005
Managing cardiovascular risk in minority patientsKeith C Ferdinand
The American Journal of Cardiology|January 31, 2006
Coronary artery disease in minority racial and ethnic groups in the United StatesKeith C Ferdinand
Current Medical Research and Opinion|July 12, 2005
Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular diseaseKeith C Ferdinand
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 9, 2008
Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?Keith C Ferdinand
Expert Opinion on Pharmacotherapy|September 8, 2005
Rosuvastatin: a risk-benefit assessment for intensive lipid loweringKeith C Ferdinand
Pageof 29